Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a gentle brain zap help control blood pressure?

NCT ID NCT07239492

Disease control Sponsor: Xuanwu Hospital, Beijing Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether a non-invasive brain stimulation technique called temporal interference can safely help regulate blood pressure. Researchers will enroll 25 adults with either mild untreated hypertension or hard-to-treat hypertension, as well as people with low blood pressure. Participants will receive 20-minute sessions over 5 days, and their blood pressure will be monitored for 4 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
temporal interference stimulation
What this could lead to
If it works, this could offer a non-invasive, drug-free way to help manage blood pressure.
What could go wrong
This is a very small, early pilot study with only 25 people. It may not show clear results or work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age: 18-65 years old, male or female; 2. Three groups of patients will be enrolled in the study: 1. Essential Hypertension Grade 1 (Low Risk) - Antihypertensive Medication-Naive Group: No other cardiovascular risk factors or disease history, with systolic blood pressure (SBP) ≥140 mmHg and \<160 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg and \<100 mmHg; 2. Essential Hypertension - Refractory Hypertension Group: Meeting one of the following conditions after intensive lifestyle intervention plus taking 3 different types of antihypertensive drugs (including thiazide diuretics) for ≥4 weeks, with each drug at the maximum dose or maximum tolerated dose: Clinic blood pressure ≥140/90 mmHg and 24-hour average ambulatory blood pressure ≥130/80 mmHg, or average home blood pressure ≥135/85 mmHg; or blood pressure can only be controlled below 140/90 mmHg with ≥4 types of antihypertensive drugs; 3. Neurogenic Orthostatic Hypotension (nOH) Group: A decrease in SBP ≥20 mmHg and/or DBP ≥10 mmHg within 3 minutes of the head-up tilt test (HUTT) and/or standing activity; 3. BMI: 18-30; 4. After being informed of the potential risks, the patient agrees to participate in this study and signs the informed consent form (ICF). Exclusion Criteria: 1. Patients with secondary hypertension; 2. Patients with intracranial structural lesions (e.g., infarcts, vascular malformations, space-occupying lesions, etc.); 3. Pregnant women; 4. Individuals unable to cooperate due to mental illness or other reasons; 5. Those who have participated in other clinical studies within the past 3 months; 6. Patients who apply to withdraw from this clinical study for any reason; 7. Patients with cardiac insufficiency; 8. Patients excluding those with white coat effect; 9. Individuals with a high risk of cerebrovascular disease confirmed by transcranial magnetic resonance imaging (MRI).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Essential hypertension grade 1 (low risk) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

essential hypertension hypertensive disorder hypotensive disorder primary orthostatic hypotension resistant hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension Hypotension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Xuanwu Hospital,Capital Medical University, Beijing, Beijing 100053

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.